Company:  DARA BIOSCIENCES, INC. (DARA)
Form Type:  8-K
Filing Date:  10/22/2013 
CIK:  0000919745 
Address:  8601 SIX FORKS ROAD SUITE 160 
City, State, Zip:  RALEIGH, North Carolina 27615 
Telephone:  (816) 914-7027 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.88  
Change: 
0.00 (0.00%)  
Trade Time: 
Apr 24  
Market Cap: 
$15.80M
Description of Business
DARA BioSciences, Inc. (NASDAQ: DARA) is a North-Carolina based specialty pharmaceutical company primarily focused on the commercialization of oncology treatment and oncology supportive care pharmaceutical products. Through our acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, we acquired exclusive U.S. marketing rights to our first commercial, FDA-approved proprietary product Soltamox� (tamoxifen citrate) oral solution. Soltamox has been approved by the U.S. Food and Drug Administration (�FDA�) for the prevention and treatment of breast cancer. On September 7, 2012, we entered into a license agreement with Helsinn Healthcare SA (�Helsinn�) to distribute, promote, market and sell Gelclair�, a unique oral gel whose key ingredients are polyvinlypyrrolidone (PVP) and sodium hyaluronate (hyaluronic acid), for the treatment of certain approved indications in the United States. Gelclair is an FDA-cleared product indicated for the treatment of oral mucositis.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 1 BUSINESS AND OPERATIONS
      Item 1.01. Entry Into a Material Definitive Agreement.
      Item 1.02. Termination of a Material Definitive Agreement.
    SECTION 3 SECURITIES AND TRADING MARKETS
      Item 3.02. Unregistered Sales of Equity Securities.
    SECTION 8 OTHER EVENTS
      Item 8.01. Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES
  EXHIBIT 1.1
  EXHIBIT 4.1
  EXHIBIT 5.1
  EXHIBIT 10.1
  EXHIBIT 99.1
BROKERAGE PARTNERS